SEC Company Response from NEKTAR THERAPEUTICS (NKTR) (CIK 0000906709) (NKTR) — Jan 14, 2009
NEKTAR THERAPEUTICS (NKTR) (CIK 0000906709)
Date: Jan. 14, 2009 · CIK: 0000906709 · Accession: 0001144204-09-002006
AI Filing Summary & Sentiment
File numbers found in text: 000-24006
Referenced dates: December 10, 2008
Letter
Securities and Exchange Commission Division of Corporate Finance Washington, D.C. 20549 Attention: Nandini Acharya, Esq. Re: Nektar Therapeutics. -- Form 10-K for the Year Ended December 31, 2007 (File No. 000-24006)
Dear Ms. Acharya:
This request is in relation to the letter dated December 10, 2008 (the “Comment Letter”), including comments from the staff of the Securities and Exchange Commission to the Form 10-K for the year ended December 31, 2007 (File No. 000-24006) filed by Nektar Therapeutics, a Delaware corporation, on February 29, 2008.
We respectfully request an extension to January 23, 2009 to provide a response to the Comment Letter.
Please do not hesitate to call the undersigned at (650) 620-5990 or Jennifer A. DePalma, Esq. of O’Melveny & Myers LLP, legal counsel to Nektar Therapeutics, at (650) 473-2670, regarding this matter.
Sincerely,
/s/
Gil M. Labrucherie
Show Raw Text
CORRESP
1
filename1.htm
Nektar
Therapeutics
201
Industrial Road
San
Carlos, California 94070
Sender
Contact Information
P: (650)
620-5990
F: (650)
620-5360
January
14, 2009
VIA FACSIMILE AND U.S.
MAIL
Securities
and Exchange Commission
Division
of Corporate Finance
Washington,
D.C. 20549
Attention: Nandini
Acharya, Esq.
Re:
Nektar Therapeutics. -- Form 10-K for the Year
Ended December 31, 2007 (File No.
000-24006)
Dear Ms.
Acharya:
This
request is in relation to the letter dated December 10, 2008 (the “Comment Letter”), including
comments from the staff of the Securities and Exchange Commission to the Form
10-K for the year ended December 31, 2007 (File No. 000-24006) filed by Nektar
Therapeutics, a Delaware corporation, on February 29, 2008.
We
respectfully request an extension to January 23, 2009 to provide a response to
the Comment Letter.
Please do
not hesitate to call the undersigned at (650) 620-5990 or Jennifer A. DePalma,
Esq. of O’Melveny & Myers LLP, legal counsel to Nektar Therapeutics, at
(650) 473-2670, regarding this matter.
Sincerely,
/s/
Gil M. Labrucherie
Gil
M. Labrucherie
Senior
Vice President, General Counsel &
Secretary
of Nektar
Therapeutics
cc:
Howard
W. Robin, President and Chief Executive Officer of Nektar
Therapeutics
Sam
Zucker, Esq., O’Melveny & Myers LLP
Jennifer
A. DePalma, Esq., O’Melveny & Myers
LLP